The latest clinical guidelines from the American College of Gastroenterology aim to improve the diagnosis and treatment of ...

Budesonide has not been shown to be safe and effective for the treatment of EoE for longer than 12 weeks. Additionally, the FDA recently approved dupilumab for pediatric patients aged one to ...

Topical steroids taken daily or twice daily do not result in significantly varying outcomes among individuals with eosinophilic esophagitis.

Traditionally, this finding has been attributed solely to peptic injury, but with the advent of EoE, a second potential etiologic entity is recognized. Some patients may exhibit clinical features ...

The US regulator has cleared Eohilia (formerly TAK-721), an oral suspension formulation of the well-established steroid drug budesonide, for people 11 years and older with EoE after turning down ...

TAK-721 – provisionally known as Eohilia - is an oral suspension formulation of the well-established steroid drug budesonide that ... merger with Shire in 2019. EoE is a chronic condition ...

The treatment of EoE pursues several goals: control of symptoms, correction of complications and prevention of long-term sequelae. A significant proportion of patients with low-grade esophageal ...

Discover top medications for 'treating Eosinophilic Esophagitis (EoE)'? This page compiles essential information on generic and brand-name drugs specifically used for Eosinophilic Esophagitis (EoE ...

The pipeline for Eosinophilic Esophagitis is strong, with many candidates like VELSIPITY, TEZSPIRE, ESO-101, Cendakimab and others. In February 2024, the US FDA approved EOHILIA (budesonide oral ...